Scientific progress can’t help people if they can’t access care This is a policy problem. And it is one we can change.

Nutritional supplement may help ease brain fog after breast cancer treatment, UCLA study finds

A nutritional supplement containing oxaloacetate, a molecule naturally found in the body that helps cells produce energy, may help improve cognitive function and reduce the fatigue experienced by some breast cancer survivors following treatment, according to a study led by researchers at the UCLA Health Jonsson Comprehensive Cancer Center.

October 23, 2026

Vol.52 No.39

Beyond BRCA: Using AI to uncover the hidden architecture of hereditary cancer risk

A Fox Chase Cancer Center team is combining a rare longitudinal family cohort, whole-genome sequencing, AI-guided analysis, and laboratory validation to investigate why people with similar inherited susceptibility can experience very different cancer outcomes.

October 16, 2026

Vol.52 No.38

By Fox Chase Cancer Center

Clinical Roundup

ACS studies find widening rural-urban survival and mortality gaps for women with breast cancer

Life-saving advances in breast cancer care are failing to reach rural America equally. In two large studies led by the American Cancer Society, scientists found that survival and mortality disparities between rural and urban women diagnosed with breast cancer widened over time in the United States.

October 16, 2026

Vol.52 No.38

Perspective

Oncology has a semantics problem: How do we define “early stage”?

I recently found myself asking a question that I thought had an obvious answer: What is early-stage cancer?

FDA approves tucatinib + trastuzumab + pertuzumab for maintenance treatment of HER2+ breast cancer

FDA approved Tuksya (tucatinib) in combination with trastuzumab and pertuzumab for the maintenance treatment of adults with unresectable locally advanced or metastatic human epidermal growth factor 2-positive breast cancer following induction treatment. The approval expands the use of Tuksya to frontline, an earlier stage of metastatic disease, offering a new chemotherapy-free maintenance treatment option that may help further delay disease progression.

October 09, 2026

Vol.52 No.37

Regulatory News

Two years after FDA’s breast density notification rule, there is still no standard for follow-up
So far, 38 million patients have received a dense breast notification. Now what?

Nearly two years after FDA issued a final rule requiring radiologists to tell women whether their breasts are “dense” or “not dense” after a mammogram, the notification has become nearly universal.

October 02, 2026

Vol.52 No.36

By Claire Marie Porter

Scientific progress can’t help people if they can’t access care

This is a policy problem. And it is one we can change.

YOU MAY BE INTERESTED IN

Nutritional supplement may help ease brain fog after breast cancer treatment, UCLA study finds

Beyond BRCA: Using AI to uncover the hidden architecture of hereditary cancer risk

ACS studies find widening rural-urban survival and mortality gaps for women with breast cancer

Oncology has a semantics problem: How do we define “early stage”?

FDA approves tucatinib + trastuzumab + pertuzumab for maintenance treatment of HER2+ breast cancer

Two years after FDA’s breast density notification rule, there is still no standard for follow-up
So far, 38 million patients have received a dense breast notification. Now what?

Renew today!

Subscriber content

Never miss an issue!

Login

Scientific progress can’t help people if they can’t access care

This is a policy problem. And it is one we can change.

YOU MAY BE INTERESTED IN

Nutritional supplement may help ease brain fog after breast cancer treatment, UCLA study finds

Beyond BRCA: Using AI to uncover the hidden architecture of hereditary cancer risk

ACS studies find widening rural-urban survival and mortality gaps for women with breast cancer

Oncology has a semantics problem: How do we define “early stage”?

FDA approves tucatinib + trastuzumab + pertuzumab for maintenance treatment of HER2+ breast cancer

Two years after FDA’s breast density notification rule, there is still no standard for follow-upSo far, 38 million patients have received a dense breast notification. Now what?

Never miss an issue!

Login

Two years after FDA’s breast density notification rule, there is still no standard for follow-up
So far, 38 million patients have received a dense breast notification. Now what?